Tri-Modal Excipient, Multi-Route Delivery: A Systematic Review of How Capryol® 90 Drives Nano-Drug Delivery (2018–2025)

Read full text Summarise with VIRAT
Authors: Bakr Ahmed, Abdulsalam Alhalmi, Dyandevi M. Mathure, Mohammad Kashif Iqubal
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This systematic review comprehensively evaluates original research articles and patents published between 2018 and 2025 that investigate the role of Capryol® 90 (propylene glycol monocaprylate) in lipid-based nano-drug delivery systems. The aim is to assess its tri-modal functionality—as a solubilizer, lipid matrix softener, and epithelial permeation enhancer—across various administration routes, including oral, dermal, ocular, intranasal, and pulmonary. Following PRISMA 2020 guidelines, 21 original studies and 11 patent families were analyzed, with findings mapped by formulation type (e.g., NLCs, SNEDDS, nanoemulsions) and therapeutic domain. Capryol® 90 demonstrated enhancement in encapsulation efficiency, stability, bioavailability, and mucosal penetration in most formulations. This review also outlines regulatory considerations, limitations in translational progress, and identifies future research needs such as chronic safety data and device compatibility. The review supports Capryol® 90’s emerging role as a keystone excipient in advanced nanoformulations.

Fields of Study & Subjects

Drug Solubulity and Delivery Systems Advancements in Transdermal Drug Delivery Advanced Drug Delivery Systems

Publication details

Publication date
30 March 2026
Language
EN
Document type
Preprint